EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [41] Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia
    M Paganin
    M Zecca
    G Fabbri
    K Polato
    A Biondi
    C Rizzari
    F Locatelli
    G Basso
    Leukemia, 2008, 22 : 2193 - 2200
  • [42] HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA (ALL) - IS THERE AN ALTERNATIVE APPROACH FOR INCREASING THE NUMBER OF CURES
    CARELLA, AM
    HAEMATOLOGICA, 1992, 77 (04) : 348 - 351
  • [43] LYMPHOMATOUS PRESENTATION OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - A SUBGROUP AT HIGH-RISK OF EARLY TREATMENT FAILURE
    STEINHERZ, PG
    SIEGEL, SE
    BLEYER, WA
    KERSEY, J
    CHARD, R
    COCCIA, P
    LEIKIN, S
    LUKENS, J
    NEERHOUT, R
    NESBIT, M
    MILLER, DR
    REAMAN, G
    SATHER, H
    HAMMOND, D
    CANCER, 1991, 68 (04) : 751 - 758
  • [44] FAILURE OF PURGED AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA IN 1ST COMPLETE REMISSION
    GILMORE, MJML
    HAMON, MD
    PRENTICE, HG
    KATZ, F
    SLAPERCORTENBACH, ICM
    HUNTER, AE
    GANDHI, L
    BRENNER, MK
    HOFFBRAND, AV
    MEHTA, AB
    SECKERWALKER, LM
    SKEGGS, D
    COLLIS, CH
    BONE MARROW TRANSPLANTATION, 1991, 8 (01) : 19 - 26
  • [45] MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA - PCR ANALYSIS OF IMMUNOGLOBULIN GENE REARRANGEMENTS
    COLESINCLAIR, M
    FORONI, L
    WRIGHT, F
    MEHTA, A
    PRENTICE, HG
    HOFFBRAND, AV
    LEUKEMIA & LYMPHOMA, 1993, 11 : 49 - 58
  • [46] GENE REARRANGEMENTS AS MARKERS OF CLONAL VARIATION AND MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    WRIGHT, JJ
    POPLACK, DG
    BAKHSHI, A
    REAMAN, G
    COLE, D
    JENSEN, JP
    KORSMEYER, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (05) : 735 - 741
  • [47] TREATMENT OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - THE GERMAN NATIONAL STUDY
    HOELZER, D
    THIEL, E
    LOFFLER, H
    BUCHNER, T
    BODENSTEIN, D
    ENGELHARDT, R
    RUHL, H
    GANSER, A
    ZWINGERS, T
    MESSERER, D
    LEUKEMIA RESEARCH, 1986, 10 (01) : 89 - 89
  • [48] GENETIC CHANGES - RELEVANCE FOR DIAGNOSIS AND DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    COLESINCLAIR, MF
    FORONI, L
    HOFFBRAND, AV
    BAILLIERES CLINICAL HAEMATOLOGY, 1994, 7 (02): : 183 - 233
  • [49] Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
    Camargos Rocha, Juliana Maria
    Xavier, Sandra Guerra
    de Lima Souza, Marcelo Eduardo
    Assumpcao, Juliana Godoy
    Murao, Mitiko
    de Oliveira, Benigna Maria
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2016, 8
  • [50] ACUTE LYMPHOBLASTIC-LEUKEMIA OF CHILDHOOD - RESULTS OF A THERAPY PROTOCOL INCLUDING BONE-MARROW TRANSPLANTATION DURING THE 1ST REMISSION FOR HIGH-RISK PATIENTS
    MICHEL, G
    MARANINCHI, D
    THURET, I
    FAY, C
    GUITARD, AM
    MOZZICONACCI, MJ
    NOVAKOVITCH, G
    CAPODANO, AM
    TUBIANA, N
    PERRIMOND, H
    ARCHIVES FRANCAISES DE PEDIATRIE, 1990, 47 (03): : 163 - 168